Abstract
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) was established in 1986 to develop standard methods to evaluate persons with Alzheimer’s disease (AD) and to gather clinical, neuropsychological, and neuropathological information about the illness (Morris et al., 1989). Rather than a true registry, CERAD utilized convenience samples from 24 U.S. AD research centers to accomplish its aims of standardizing and testing the reliability of brief assessment instruments for AD and thus provide tools for use in epidemiologic surveys, dementia registries, and AD research protocols, including clinical drug trials. Since the onset of patient recruitment in 1987, CERAD has enrolled 1,281 cases and 472 controls into its longitudinal studies. Analyses of the CERAD database have addressed clinical diagnostic accuracy, neuropsychological staging of dementia severity, rates of cognitive decline, and other issues in the clinico-pathological characterization of AD.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
